Loading...
•
Jun 30, 2021
Palatin Technologies Q4 2021 Earnings Report
Palatin Technologies reported results for the fourth quarter and fiscal year ended June 30, 2021.
Key Takeaways
Palatin Technologies reported a net loss of $13.9 million for the quarter ended June 30, 2021. The company's cash and cash equivalents were $60.1 million as of June 30, 2021, providing a cash runway through calendar year 2022.
Phase 3 pivotal study of PL9643 in patients with dry eye disease is expected to start next quarter, with top-line results expected in the second half of calendar year 2022.
Phase 2 clinical study of PL8177 in patients with ulcerative colitis is expected to start next quarter, with top-line results expected in the second half of calendar year 2022.
Cash and cash equivalents were $60.1 million at June 30, 2021, projecting a cash runway through calendar year 2022.
Vyleesi gross sales for the quarter amounted to $1.2 million with net product revenue of $80,504.
Palatin Technologies
Palatin Technologies
Forward Guidance
Palatin Technologies believes that existing cash and cash equivalents will be sufficient to fund currently anticipated operating expenses through the end of calendar year 2022.